Telli ML, Witteles RM, Fisher GA et al.
Stanford University, Stanford, CA, USA.
Ann Oncol 2008;19:1613–8.Editor’s note:
Management of “off-target” effects of the novel targeted agents in oncology remains a challenge. This important area requires further investigation, as the early diagnosis and treatment of unwanted drug effects may improve patient compliance and avoid dose reduction and delays, thus maximizing the efficacy of the anticancer therapy.